HCM
PCRX icon

Hodges Capital Management’s Pacira BioSciences PCRX Stock Holding History

Hodges Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,800
Closed -$415K – 221
2022
Q3 		$415K Buy
7,800
+2,650
+51% +$147K 0.07% 160
2022
Q2 		$300K Sell
5,150
-162,562
-97% -$10.6M 0.03% 190
2022
Q1 		$12.8M Sell
167,712
-238
-0.1% -$15.9K 1.02% 30
2021
Q4 		$10.1M Buy
+167,950
New +$9.26M 0.73% 48
2021
Q2 		– Sell
-75,245
Closed -$5.27M – 243
2021
Q1 		$5.27M Buy
+75,245
New +$5.37M 0.73% 48
2017
Q4 		– Sell
-7,000
Closed -$263K – 262
2017
Q3 		$263K Buy
7,000
+2,000
+40% +$80.5K 0.02% 234
2017
Q2 		$238K Sell
5,000
-140,000
-97% -$6.5M 0.01% 243
2017
Q1 		$6.61M Sell
145,000
-14,000
-9% -$605K 0.33% 82
2016
Q4 		$5.14M Buy
+159,000
New +$5.31M 0.24% 90
2015
Q2 		– Sell
-295,294
Closed -$26.2M – 307
2015
Q1 		$26.2M Buy
295,294
+1,034
+0.4% +$105K 1% 30
2014
Q4 		$26.1M Buy
294,260
+30,480
+12% +$2.88M 1.06% 24
2014
Q3 		$25.6M Buy
263,780
+33,530
+15% +$3.26M 1.06% 20
2014
Q2 		$21.2M Buy
230,250
+915
+0.4% +$69.7K 0.99% 22
2014
Q1 		$16.1M Sell
229,335
-5,890
-3% -$401K 0.94% 27
2013
Q4 		$13.5M Sell
235,225
-77,005
-25% -$4.05M 0.97% 26
2013
Q3 		$15M Buy
+312,230
New +$11.4M 1.3% 12

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Hodges Capital Management's PCRX Position: Q4 2022 in Review

Hodges Capital Management sold out of Pacira BioSciences (PCRX) in Q4 2022, closing a stake of 7,800 shares — an estimated $415K sold.

Hodges Capital Management first reported a position in PCRX in Q3 2013 and held it in 16 quarters. The position peaked at $26.2M in Q1 2015. 273 funds tracked by Wall St. Rank hold PCRX as of Q4 2022.

  • Hodges Capital Management reported no remaining Pacira BioSciences position as of Q4 2022 after selling out during the quarter.
  • Hodges Capital Management sold 7,800 Pacira BioSciences shares in Q4 2022, an estimated $415K.
  • Hodges Capital Management first reported a position in Pacira BioSciences in Q3 2013 and held it in 16 quarters.
  • Hodges Capital Management's Pacira BioSciences position peaked at $26.2M in Q1 2015.
  • 273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2022.

Based on Hodges Capital Management's 13F filing for Q4 2022, filed 3 Feb 2023.